The National Reference Laboratory (NRL) has announced a significant advancement in cancer diagnostics in the United Arab Emirates through the introduction of an AI-powered prostate cancer diagnostic solution developed in collaboration with M42 and Qritive. This initiative marks a major step forward in the integration of digital pathology and artificial intelligence within the region’s healthcare ecosystem.
The newly introduced solution is designed to enhance the accuracy, speed, and consistency of prostate cancer detection by leveraging advanced AI algorithms alongside digital pathology workflows. By combining clinical expertise with next-generation technology, the system aims to support pathologists in making more precise and timely diagnostic decisions, ultimately improving patient outcomes.
Prostate cancer remains one of the most common cancers affecting men globally, and early detection plays a critical role in effective treatment and survival rates. Traditional pathology methods, while highly reliable, can be time-intensive and dependent on manual interpretation. The integration of AI-powered tools addresses these challenges by assisting in the analysis of complex tissue samples and reducing the risk of diagnostic variability.
Bruno Occhipinti, CEO, Qritive, said: “We are proud to collaborate with NRL, an institution that share our belief that AI is critical in augmenting pathologist capacity at a time when rising disease occurrences are placing growing pressure on healthcare systems. This deployment reflects a shared commitment to delivering high-quality, technology-enabled, and compassionate care for the region.”
Through this collaboration, M42 contributes its expertise in large-scale healthcare transformation and data-driven clinical innovation, while Qritive provides its advanced artificial intelligence technology specializing in digital pathology. The National Reference Laboratory serves as the operational and clinical implementation hub, ensuring that the solution is effectively integrated into real-world diagnostic workflows within the UAE healthcare system.
Also Read: Everest Medicines Secures LNZ100 Deal in Greater China
The AI-enabled platform is capable of analyzing digitized biopsy samples with high precision, identifying patterns that may indicate the presence or progression of prostate cancer. It is designed to act as a decision-support tool for pathologists rather than a replacement, enhancing their capabilities and allowing them to focus on more complex diagnostic evaluations.
Healthcare leaders involved in the initiative emphasized the importance of combining innovation with clinical reliability. The adoption of AI in pathology is expected to significantly reduce turnaround times for diagnostic reports, enabling faster treatment planning for patients. Additionally, the technology supports standardization in reporting, ensuring greater consistency across laboratories.
This development aligns with the UAE’s broader vision of adopting advanced technologies to strengthen its healthcare infrastructure and position itself as a global hub for medical innovation. The use of artificial intelligence in oncology diagnostics reflects a growing shift toward precision medicine, where treatment decisions are increasingly guided by data-driven insights.
Experts also highlight that such innovations are particularly impactful in high-demand diagnostic environments, where pathology departments handle large volumes of samples daily. By automating routine image analysis tasks, the AI system allows laboratory professionals to allocate more time to complex cases and multidisciplinary collaboration.
The introduction of this solution is expected to pave the way for further expansion of AI applications across other disease areas in pathology, including breast, lung, and gastrointestinal cancers. It also sets the foundation for broader adoption of digital pathology systems across healthcare institutions in the region.
As healthcare systems continue to evolve, partnerships between diagnostic laboratories, technology providers, and healthcare platforms are becoming increasingly essential. This collaboration between the National Reference Laboratory, M42, and Qritive represents a strong example of how cross-sector innovation can drive meaningful improvements in clinical care.
The initiative underscores a shared commitment to advancing early detection, improving diagnostic accuracy, and ultimately enhancing patient care outcomes through the responsible use of artificial intelligence in medicine.
